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Abstract
Objectives Left ventricular mass (LVM) at cardiac magnetic
resonance imaging (CMR) is a frequent end point in clinical
trials in nephrology. Trial participants with end stage renal
disease (ESRD) may have a greater frequency of incidental
findings (IF). We retrospectively investigated prevalence of IF
in previous research CMR and reviewed their subsequent im-
pact on participants.
Methods Between 2002 and 2006, 161 ESRD patients
underwent CMR in a transplant assessment study. Images
were used to assess LVmass and function. In the current study
a radiologist reviewed the scans for IF. Review of patient
records determined the subsequent clinical significance of IF.
Results There were 150 IF in 95 study participants. Eighty-
four (56 %) were new diagnoses. One hundred and two were
non-cardiac. Fifteen were suspicious of malignancy. There
was a clinically significant IF for 14.9 % of the participants.
In six cases earlier identification of an IF may have improved
quality of life or survival.
Conclusions Without radiology support clinically important
IF may bemissed on CMR. Patients undergoing CMR in trials
should be counselled about the frequency and implications of
IF. Patients with ESRD have a higher prevalence of IF than
reported in other populations. Nephrology studies require
mechanisms for radiologist reporting and strategies for deal-
ing with IF.
Key Points
• Incidental findings on research cardiac magnetic resonance
imaging can have significant consequences.
• We considered incidental findings in historical renal cardiac
resonance imaging clinical trials.
• Incidental findings are common and important in the chron-
ic kidney disease population.
• Without radiology support, clinically significant incidental
findings may be missed on imaging.
• Study protocols, approvals and consent processes should
take account of possible findings.
Keywords Chronic kidney disease . Clinical trials . MRI .
Incidental findings . CMR
Abbreviations
CKD Chronic kidney disease
CMR Cardiac magnetic resonance imaging
ESRD End stage renal disease
HOCM Hypertrophic obstructive cardiomyopathy
IF Incidental findings
LVH Left ventricular hypertrophy
LVM Left ventricular mass
Introduction
Reduction in cardiac morbidity and mortality is of great im-
portance in nephrology. Within the chronic kidney disease
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(CKD) population, increased left ventricular mass (LVM) is
well established as a surrogate marker of cardiovascular risk
[1]; therefore, reduction in LVM assessed by cardiac magnetic
resonance imaging (CMR) is a frequent primary end point in
nephrology clinical trials [2–9].
Patients consenting to participate in clinical trials undergo
CMR that would not otherwise be performed. Standard CMR
imaging techniques commonly capture windows out with the
area of the heart including the abdomen and thorax. Clearly
incidental findings (IF) on images obtained for research may
have unexpected clinical consequences. The prevalence of
unexpected findings in clinically indicated CMR has been
well documented [10–13]. While the reported incidence of
incidental non-cardiac findings in non-renal populations
varies from around 7-27 %, the rate of clinically significant
IF is much lower than this at around 1-7 % [10–13]. The rate
of IF in CMR performed for research purposes is less well
established [14]. However, findings in research CMR are im-
portant and current radiology guidelines reflect this [15].
Trial participants with CKD may be at increased risk of
having clinically significant IF. In those with end stage renal
disease (ESRD) the risk may be even greater as these individ-
uals are likely to have a larger burden of ill health. This po-
tential increased risk of IF could have ethical, clinical and
financial implications for future CMR nephrology studies
and their participants. The prevalence of IF in CMR in patients
with ESRD requiring dialysis is unknown. To investigate this,
we retrospectively determined the prevalence of IF in previous
research CMR and reviewed its potential subsequent impact
on patient care.
Subjects and methods
Participants
Between 2002 and 2006, 161 patients underwent CMR as part
of a prospective single centre research study considering car-
diac risk and transplantation assessment under the care of the
Renal Transplant Unit at theWestern Infirmary Glasgow [8, 9,
16, 17]. All participants had CKD stage 5 (estimated glomer-
ular filtration rate<15/min) and were receiving peritoneal or
haemodialysis, or were within 6 months of requiring it (pre-
dialysis). Participants had no contraindications to CMR but
were otherwise an unselected group. The study was approved
by the local ethics committee. Prior to imaging, all participants
provided written informed consent.
CMR acquisition and analysis
CMR imaging was performed using a 1.5-Tesla magnetic res-
onance imaging scanner (Sonata, Siemens Erlangen,
Germany). In the original study, images were used by our
research group solely to assess cardiac parameters, in particu-
lar LVM and cardiac function. For those on haemodialysis, the
scans were consistently performed 24 hours after the end of
the last dialysis session. Following acquisition of localizer
images using a gradient echo sequence (FLASH:
TR=3.25 ms; TE=1.6 ms; FA=250; pixel area=1.4 mm by
1.4 mm; slice thickness=8 mm; FOV=360 mm) a steady-
state free precession (TrueFISP) sequence was used to acquire
cine images in three long axis planes (vertical long axis, hor-
izontal long axis, left ventricular outflow tract) followed by
short axis sequences from the atrioventricular ring to the apex.
Cine sequences were obtained with the following acquisition
parameters: TR = 3.14 ms; TE = 1.6 ms; FA = 600; pixel
area = 2.2 mm by 1.3 mm; slice thickness = 8 mm;
FOV=340 mm. Evidence of prior infarcts was sought on
short axis late gadolinium enhancement sequences. All these
studies were performed prior to any link between the use of
gadolinium contrast agents with nephrogenic systemic fibrosis
(NSF) was established in CKD patients [18, 19]. Late gado-
linium enhancement imaging was acquired using a breath-
hold segmented turbo fast low angle shot (FLASH)
inversion-recovery sequence with the following acquisition
parameters: TR = 11.6 ms; TE = 4.3 ms; FA = 200; pixel
area = 2.2 mm by 1.3 mm; slice thickness = 8 mm;
FOV=340 mm. From March 2004, in order to assess aortic
indices, a transverse HASTE stack of the thorax was adopted
into our imaging protocol (TR = 600 ms; TE = 24 ms;
FA = 1600; pixel area = 1.4 mm by 1.4 mm; sl ice
thickness=8 mm; FOV=360 mm). From this a ‘candy cane’
TrueFISP sequence of the thoracic aorta was obtained. An
axial oblique through plane phase contrast sequence was also
obtained through the thoracic aorta at the level of the right
pulmonary artery. This was performed in 113 patients. In the
current study, an experienced radiologist from another centre
reviewed all images for IF. The reviewing radiologist was
blinded to patient identity, outcomes, original scans and sub-
sequent imaging.
IF classification
Findings were categorized as cardiac and non-cardiac IF.
Cardiac findings were sub-classified as valve, pericardial or
findings suggestive of cardiomyopathy. Multiple valve abnor-
malities on a scan were considered a single finding.
Abnormalities in ventricular mass, size, perfusion or function
were not considered IF unless consistent with a previously
undiagnosed non-uraemic cardiomyopathy.
Non-cardiac findings were subcategorized as lung/
mediastinal, pleural effusions, gastrointestinal, hepatic/renal
cysts and ‘other’ findings. Renal atrophy was not considered
an IF. Hepatic and renal cysts were not considered IF, if there
was a history of polycystic kidney disease.
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Establishing clinical significance
Current and historical electronic clinical and radiology records
for all participants with one or more IF were reviewed by a
clinician who was not involved in subsequent patient care. The
end of the follow-up period for establishing IF significance was
considered as the date of death or the date clinical records were
reviewed (if later). Whether a finding raised the possibility of
malignancy was noted. Figure 1 details the process followed
for determining the significance of IF. The clinical significance
of IF was determined by answering three questions:
& Did the finding represent a new diagnosis?
Cases where it was not possible to determine if the
finding represented a new diagnosis or not were not con-
sidered new diagnoses. Pleural effusions were only con-
sidered to be a new diagnosis if they were unilateral and at
least moderately sized.
& Did, or would, the finding have altered clinical management
at the time of imaging (e.g., further investigation or referral)?
IF were considered significant if they altered, or would
have altered patient management when recognised.
& Would earlier knowledge of the finding have feasibly al-
tered the patient’s clinical course and potentially improved
quality of life or survival?
This question was only asked of significant IF.
Statistics
Statistical analysis was performed using SPSSv21 (IBM,
Armonk, NY, USA). For normally distributed data, a t-test
was used to compare means across groups. For non-
parametric data, a Mann-Whitney test was used. Regression
analysis determined whether the presence of an IF was pre-
dictive of poorer survival.
Results
Participant characteristics
Mean age at time of imaging was 52.3 years (range 25-77
years). A full breakdown of baseline patient demographics
and available clinical data is available in Table 1. As in our
original research, there was a high prevalence of traditional
cardiovascular risk factors [9]. At the end of follow-up,
50.3 % of participants were alive. Median follow-up duration
was 10.0 years (range 1 day-12.4 years).
Incidental 
Finding? Notes not reviewed 
Finding not clinically important
Finding not clinically significant 
Finding clinically 
significant 
Outcome 
potentially 
changed by 
earlier 
knowledge?
No harm caused by lack of IF 
identification 
New 
Diagnosis? 
Should IF 
change 
management? 
Missed opportunity to initiate 
treatment or investigations for an 
important finding
No
No
No
Yes
Yes
Yes
Finding acted on at time of 
imaging
150
84
66
56
28
7
Fig. 1 Flow diagram showing the number and significance of findings at
each level of importance. The numbers represent the number of findings
at each point in the process
Table 1 Baseline demographic and clinical data for participants
Variable Total (161 participantsa)
Age at CMR (years) 52.3
Male 104 (64.6 %)
Body surface area (m2) 1.84 (±0.23)
BMI (kg/m2) 26.02 (±5.07)
Systolic blood pressure (mmHg) 138 (±25)
Diastolic blood pressure (mmHg) 82(±13)
Renal replacement therapy
Haemodialysis (%) 44.7
Peritoneal dialysis (%) 35.4
Pre-dialysis (%) 19.9
Diabetes mellitus (%) 31
Hypertension (%) 50.6
Previous myocardial infarction (%) 5.7
Ischaemic heart disease (%) 8.2
Cerebrovascular disease (%) 4.4
Peripheral vascular disease (%) 2.5
Dyslipidaemia (%) 24.7
Never Smoker (%) 53.2
Current/ Ex smoker (%) 46.8
Haemoglobin (g/dL) 11.45 (± 1.97)
Corrected calcium (mmol/l) 2.29 (±0.31)
Albumin (g/dl) 39.2 (±4.8)
Phosphate (mmol/l) 1.68 (±0.5)
CMR ejection fraction (%) 67.5 (±11.2)
CMR left ventricular mass index (g/ m2) 91.4 (±27.6)
a Full clinical demographic data was not available for 5 participants
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Participants with an IF tended to be older than those with-
out, although this was not statistically significant (mean
53.6 years vs 50.4 years, respectively, P=0.08). There was
no difference in prevalence of IF across modality of renal
replacement therapy or any other baseline characteristic.
Number and significance of findings
Review of the 161 CMR scans revealed 150 IF in 95 patients
(59 % of patients). Eighty-four (56 %) of the IF in 66 patients
would have resulted in a new diagnosis.
There were 28 significant IF that warranted further investi-
gation or a change in patient management. Twenty-four parti-
cipants had one or more significant findings (14.9 % partici-
pants). Seven significant IF were identified and acted on at the
time of imaging. There were 21 cases of potentially significant
IF where the finding was not identified at the time of imaging.
In 15 of these cases, record review confirmed that lack of inter-
vention ultimately did not harm patient outcome. In six cases,
affecting four (2.5 %) participants, lack of recognition of the
finding was a missed opportunity to initiate investigations or
treatment for a finding that later became clinically significant.
Earlier identification of these findings may have improved the
patients’ quality of life or survival (Table 2). Figure 1 illustrates
the process of determining the significance of the IF and the
number of findings at each level of significance.
Influence of imaging protocol on IF rate
There was no difference in the rate of IF in those who had a
HASTE stack performed as part of their imaging sequence
and those who did not. Contrast administration was important
for the late gadolinium enhancement IF, where it contributed
to the diagnosis of Hypertrophic Obstructive Cardiomyopathy
(HOCM). In an additional case, perfusion sequences were
useful to characterize a hepatic lesion, which was indetermi-
nate on other sequences, but showed classical enhancement of
a haemangioma. Other than these scenarios, contrast added
little to the diagnostic yield.
Cardiac findings
There were 48 cardiac IF, 34 (70.8 %) were new diagnoses. Of
these, nine (26.5 %) did, or would have warranted a change in
patient management when recognized. On one occasion earli-
er identification of a finding of HOCM may have led to an
earlier change in the patient’s treatment and potentially im-
proved quality of life.
Valve findings
Valve disease was the most common cardiac IF (34 cases, 70.8
% of cardiac findings). Table 3 gives a breakdown of which
valves were affected. Eleven findings (32.4 %) of valve dis-
ease were known about prior to CMR imaging. Valve disease
was a new diagnosis in 23 cases, in 15 (65.2 %) of these cases,
there was clear documentation that the abnormality was iden-
tified at the time of scanning. In nine of these 15 cases, no
changes to subsequent patient management were necessary. In
the remaining six cases, the diagnosis had a direct impact on
patient care (e.g., referral for valve replacement).
There were eight cases where there was no specific mention
of valve disease on available documentation. In seven of these
cases, it was clear from note review that these lesions would
not have significantly altered subsequent patient management.
In a single case, knowledge of the valve disease – severe aortic
stenosis – would have changed management, but there was in
practice insufficient time between scanning and the patient’s
death (less than 48 hours) for any changes to be effected.
Cardiomyopathy
The presence and characteristic findings of uraemic cardiomy-
opathy in this population group have been well described with
Table 2 Summary of incidental findings where earlier detection may have improved quality of life or survival
Finding on CMR CMR year Comment
Hypertrophic obstructive cardiomyopathy 2004 Eventually diagnosed 2011 following progression of symptoms
Lung lesion highly suspicious of malignancya (Fig. 5) 2004 Died of possible malignancy 2008
Oesophageal lesion highly suspicious of malignancya
(Fig. 5)
2004 Died of possible malignancy 2008
Large unilateral pleural effusion 2004 Lower lobe lobectomy for presumed adenocarcinoma 2007
Multiple suspicious splenic lesionsb (Fig. 4) 2004 Picked up incidentally on abdominal CT 2013 – resulted in 6 month unnecessary
suspension from transplant list
Multiple suspicious liver lesionsb 2004 Picked up incidentally on abdominal CT 2013 – resulted in 6 month unnecessary
suspension from transplant list
a lesions were in same participant. Cause of death on death certificate was ‘cardiac arrest’ but participant’s clinical team felt malignancy may have been
the actual cause of death – post mortem was not pursued
b lesions were in same participant
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Left Ventricular Hypertrophy (LVH) and dilatation being
prominent findings [9, 20]. The reviewing radiologist
considered that ten participants had changes that could
be broadly consistent with a cardiomyopathy. Changes
consistent with cardiomyopathy accounted for 6.7 % of
all IF and affected 6.2 % of the study population. In
four cases this was already known about prior to CMR.
In six cases this represented a new diagnosis, in two of
these new cases, potential cardiomyopathy identification
changed immediate patient management. In one case,
the findings were noted but no changes to patient man-
agement were appropriate. In three cases, no comment
was found in historical records with regard to cardiomy-
opathy. Patient outcome could conceivably have been
influenced in only one of these cases. In this case, the
radiologist considered a 2004 scan to be consistent with
HOCM – our research group interpreted these changes
as showing evidence of prior ischaemia and LVH. In
2011 this patient was diagnosed with HOCM on repeat
CMR following progressive symptoms consistent with
the diagnosis. Although HOCM is a progressive condi-
tion, better symptom control could arguably have been
achieved through earlier recognition of this IF. However
these types of finding are clearly subject to interpreta-
tion in the context of uraemic cardiomyopathy, which
has many features that may overlap with ‘early’ HOCM.
Non-cardiac findings
There were 102 non-cardiac IF affecting 43.5 % of partici-
pants. Fifty non-cardiac findings (49.0 %) were classed as
new diagnoses. Of these 50, 19 (38.0 %) warranted further
investigation or a change in patient management when iden-
tified. On five occasions, lack of recognition of such a finding
was a missed opportunity to initiate further investigations or
treatment for a finding that later became clinically significant
(Table 2). Earlier identification of these findings may have led
to a change in the patient’s clinical course and potentially
improved quality of life or survival. Table 4 gives a break-
down of the different categories of non-cardiac findings and
their ultimate impact on patient care.
Findings suggestive of malignancy
All of the 14 non-cardiac IF that would have triggered further
investigation, but ultimately did not alter the participant’s clin-
ical course, were suspicious of malignancy. In total there were
15 IF that were suspicious of malignancy. These IF and patient
outcomes are detailed in Table 5.
Influence of IF on length of survival
The presence or absence of an IF on imaging did not have any
statistically significant impact on length of survival. See Fig. 2
–KaplanMeier Death-censored survival. Estimatedmean sur-
vival: No IF 8.4 (95 % CI 7.5-9.3) years vs with an IF 8.3
(95 % CI 7.4-9.2) years.
Discussion
This is the first study looking at the rate of IF on CMR per-
formed for research purposes in the ESRD population. Our
study highlights that IF in research CMR in this population are
Table 3 Breakdown of type of incidental valve lesions
Valve lesion Number of participants
with findingsa
Aortic regurgitation 9
Aortic stenosis 22
Mitral regurgitation 10
Tricuspid regurgitation 5
a 12 participants had more than one valve lesion
Table 4 Breakdown of the
number of different types of
non-cardiac findings and their
impact on patient care
Finding classification Total number
of findings
New diagnosis Would have changed
management if identified
but did not alter clinical
course
Identification
could feasibly
have altered
clinical course
Lung or mediastinal finding 11 9 6 1
Pleural effusion 15 4 3 1
GI tract 19 12 1 3
Hepatic/Renal cyst
(Not known PKD)
50 18 1 0
Other significant finding 7 7 3 0
Total 102 50 14 5
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Table 5 Summary of incidental findings potentially suspicious of malignancy
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both common and have potentially serious clinical implica-
tions (Fig. 3). The prevalence of IF in our study population is
greater than that in several studies looking at the rate in clin-
ically indicated CMR [10, 11, 13]. In fact, it is more than
seven times greater than the rate reported by Chan in a clini-
cally robust study of 1534 consecutive clinically indicated
CMR studies (59.0 % vs 7.6 %) [10]. This is striking as
Chan’s group was examining clinically indicated CMR im-
ages and one might expect the prevalence of IF in clinically
indicated scans to be considerably higher than that of non-
clinically indicated research scans. As our scans were under-
taken purely for research purposes, we also included a limited
number of cardiac IF in our initial analysis. However, even if
cardiac IF are excluded, the prevalence of non-cardiac IF in
our study population (43.5 %) is higher than a number of
previously reported rates (range 7.6 %-27 %) [10–13, 21].
Only one major study has a rate of IF significantly higher
than ours. This study was performed specifically to determine
the rate of IF onCMR in 132 volunteers revealed IF in 81% of
participants [14]. However, this remarkably high prevalence
rate is not truly comparable to ours as this study classed a
much broader range of findings as IF (for example sternotomy
wires). Their participants were also considerably older (mean
age 74.2). Furthermore their study did not consider the subse-
quent real life clinical significance of their findings.
Not only was our rate of finding higher than in comparable
studies, our study revealed a large number of clinically signif-
icant findings. Review of our images resulted in 84 new diag-
noses in 161 studies. However, we have not considered all
new diagnoses to be clinically significant. Whilst arguably
useful to know about, asymptomatic diverticulosis or gall-
stones is unlikely to have any significant impact on any indi-
vidual (Fig. 4).
Of much more importance to trial participants is if any IF
would lead to further investigation, or to a change in their
management. Like Sohns [13], we chose to classify findings
as significant or not on this basis. Using this more stringent
definition of a significant finding, 14.9 % of our participants
had a significant new IF. This is higher than in some other
clinical studies where comparable definitions have been used
(range 0.4-7 %) [10–13]. Given such a high prevalence rate, it
is our recommendation that all potential participants in renal
studies involving CMR are counselled about the possibility of
significant findings and the impact that they could have on
their care prior to obtaining consent.
Uniquely in this study, follow-up of all patients with IF
through review of electronic records allowed us to determine
the subsequent true impact of these significant findings on
patient care. In seven cases identification of a major finding
at the time of imaging directly led to a significant change in
Table 5 (continued)
a Findings 1and 2 were in same participant, b findings 3 and 4 were in same participant
c Cause of death on death certificate was ‘cardiac arrest’ but participant’s clinical team felt malignancy may have been the actual cause of death – post
mortem was not pursued
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patient management (for example, aortic valve replacement).
Such cases may partially explain why there was no difference
in survival of those with and without findings – the actions
taken as a result of a major finding at the time of imaging may
have improved subsequent participant survival (Fig. 2).
However, the main reason why we saw no difference in sur-
vival of the two groups is likely to be due to the confounding
multiple co-morbidities of the ESRD population.
At an individual level there were cases where survival may
have been influenced had the images been reported at the time
of imaging. For four participants (six significant findings) the
abnormality was not identified at the time of imaging and an
opportunity to influence patient care at an earlier stage was
missed (Fig. 5). Those six findings are detailed in Table 1. In
order to ensure such opportunities are not missed in future
renal studies, we recommend that all research images obtained
should be reported by a suitably trained radiologist within
clinically acceptable timeframes. This is in keeping with cur-
rent radiology research guidelines [15].
We also wish to point out that early knowledge of IF is not
always an advantage. Table 5 highlights findings that could be
interpreted as being suggestive of malignancy, the findings
Fig. 3 Multiple high signal splenic lesions (arrow heads) are visible on
this short axis cine. No prior history of malignancy was present
Fig. 4 Multiple regularly spaced low signal paraspinal masses (arrow
heads) are evident on this candy cane view of the aorta. Note also the
low signal within the liver, the combination of which is consistent with
extramedullary haematopoesis in a patient with thalassaemia
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highlighted in blue were not identified at the time of imaging.
Follow up of these participants revealed that the potentially
suspicious finding did not impact on their clinical course.
Such findings are incidentalomas and their discovery at the
time of imaging may have caused considerable stress and
subjected participants to unnecessary further investigations.
Subjects could even have been harmed by IF identification,
as a number of the findings would have resulted in arguably
unnecessary transplant listing suspension until investigations
were completed. This potential risk of harm should also be
detailed to potential study participants prior to obtaining their
consent. However, the authors of this paper believe the poten-
tial benefits of early identification of potentially significant IF
far outweigh the potential risks.
Given the importance of IF within this research population,
each study should have defined protocols for how IF will be
managed. Ethical committees considering prospective ap-
proval of renal research studies should consider the implica-
tions of IF and ensure that there is a robust protocol for their
management prior to granting study approval.
It is worth highlighting that the burden of IF in research
CMR in this population is also likely to be replicated in CMR
performed for clinical reasons. Current guidelines recommend
that all individuals, regardless of presence or absence of symp-
toms, should have an echocardiogram shortly after commenc-
ing renal replacement therapy [22]. We know that increased
LVM is strongly predictive of outcome in all cases, including
those with ESRD [1, 23]. A number of studies have shown
that LVM measurement by echocardiography in this popula-
tion is less robust than by CMR [24, 25]. As the cost of CMR
falls and it is more widely available, its role in the clinical
assessment of ESRD patients is likely to expand. Future
guidelines may include assessment of LV indices with CMR.
This means the frequency of incidental findings in this popu-
lation will become more relevant as CMR is increasingly used
for baseline clinical cardiac investigations.
Finally, the link between gadolinium based contrast
used for MRI imaging and development of NSF in pa-
tients with advanced CKD, means that this study cannot
be reproduced [19, 26]. Whilst we did not find gadolinium
contrast necessary in all cases to delineate the nature of an
IF, it is likely that further studies in the ESRD population
may require follow-up imaging with computed tomography
with iodinated contrast to follow up on indeterminate find-
ings of non-contrast CMR.
Limitations
Our study is a retrospective study using historical images.
Given the number and significance of findings discovered, a
prospective study would be ethically entirely inappropriate.
Undoubtedly methods of determining what constitutes an
IF will vary slightly between studies and reporters, and it has
not been possible to adjust for this.
In studies such as ours, where a further focused reading of
the CMR images has taken place, it might be expected that the
rate of findings would be slightly greater than in other studies.
For example, Wyttenbach [27] found the rate of significant IF
identified increased from 11.7 % to 20.5 % when the same
clinician re-interpreted historical clinical scans specifically
looking for extra-cardiac IF. However, this does not detract
from the overall value of this study, which highlights that IF in
research CMR in the ESRD population are both common and
important.
Conclusions
This study of 161 CMR images performed for research pur-
poses in the CKD5 population revealed 150 IF. 14.9 % of the
participants had a new significant IF that warranted further
investigation or a change in their management.
The prevalence of IF in the ESRD population is such
that all investigators planning studies undertaking CMR
must take proper account of it. All investigators should
consult with experienced radiologists early in the trial
planning phase to ensure an appropriate mechanism for
reporting is in place. Funding for radiologist reporting
should be factored into grant applications. All images
obtained should be reported by a qualified radiologist
within a clinically acceptable timeframe.
All potential participants in renal CMR research studies
should be counselled about the frequency and implications
of possible IF and protocols for managing IF should be part
of good clinical research practice.
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